Bio-Techne (MEX:TECH) Moat Score: 6/10 (As of Jun. 30, 2026)


MEX:TECH Bio-Techne Corp MEX:TECH
83 GF Score
Price MXN1,090.00
GF Value MXN1,114.44
! 8 Warning Signs
View Full Analysis

What is Bio-Techne Moat Score?

Bio-Techne MEX:TECH 83 Moat Score is 6 as of Jun. 30, 2026. GuruFocus rates MEX:TECH with a GF Score™ of 83/100 and a GF Value™ of MXN1,114.44. The stock has 8 warning signs investors should review. Among 1,401 Biotechnology companies, Bio-Techne ranks better than 98.93% on this metric.

Bio-Techne has the Moat Score of 6, which implies that the company might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

Bio-Techne has Narrow Moat: Bio-Techne has a strong narrow moat due to its valuable intellectual property and patents in biotechnology. It enjoys solid brand recognition and customer loyalty in niche markets. However, while it has some pricing power and innovation capabilities, these are not sufficient to classify it as a wide moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Bio-Techne might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

Bio-Techne  (MEX:TECH) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Bio-Techne Moat Score Related Terms

MEX:TECH vs ARWR, CYTK, KRYS: Moat Score Comparison

For the Biotechnology subindustry, Bio-Techne's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bio-Techne Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bio-Techne's Moat Score distribution charts can be found below:

* The bar in red indicates where Bio-Techne's Moat Score falls into.


MEX:TECH
83GF Score
Bio-Techne Corp MEX:TECH
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 6 mean?
Bio-Techne (MEX:TECH) has a Moat Score of 6 as of Jun. 30, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Bio-Techne ranks #15 out of 1401 companies in the Biotechnology industry, placing it in the top 1.1%.
Is Bio-Techne's Moat Score too high?
Bio-Techne's current Moat Score is 6. The Biotechnology industry median Moat Score is 2.00. Bio-Techne's value of 6 is 200% above this industry median. Based on the distribution chart, Bio-Techne ranks #15 out of 1401 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Bio-Techne has a GF Score™ of 83/100, reflecting its overall financial health beyond just this single metric.
How does Bio-Techne's Moat Score compare to ARWR and CYTK?
According to the Biotechnology industry distribution chart, Bio-Techne ranks #15 out of 1401 companies for Moat Score. This places Bio-Techne in the top 1% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Bio-Techne's value of 6 is 200% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,401 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bio-Techne's current Moat Score of 6 is 200% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio-Techne's current Moat Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Techne stock overvalued right now?
Bio-Techne (MEX:TECH) has a current Moat Score of 6. The stock's GF Value™ is MXN1,114.44, compared to a current price of MXN1,090.00 — trading 2.2% below its estimated fair value. The current Moat Score is 6 and 200% above the Biotechnology industry median of 2.00. Bio-Techne's overall GF Score™ is 83/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Bio-Techne (MEX:TECH), the current Moat Score is 6 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bio-Techne (MEX:TECH) Overvalued in 2026?

Based on GuruFocus' analysis, Bio-Techne stock appears to be undervalued. The current stock price of MXN1,090.00 is trading 2.2% below its estimated GF Value™ of MXN1,114.44.

Key valuation signals for MEX:TECH:

  • Moat Score: 6
  • GF Value™: MXN1,114.44 vs. price of MXN1,090.00 (2.2% below fair value)
  • GF Score™: 83/100 with 8 warning signs
  • Industry Position: 200% above the Biotechnology median (#15 of 1401)

No single metric tells the full story. See the MEX:TECH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bio-Techne Business Description

Address 614 McKinley Place N.E., Minneapolis, MN, USA, 55413
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
83GF Score

Get the complete analysis for MEX:TECH

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,090.00
Price
MXN1,114.44
GF Value